Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

87 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Fludarabine and mitoxantrone followed by yttrium-90 ibritumomab tiuxetan in previously untreated patients with follicular non-Hodgkin lymphoma trial: a phase II non-randomised trial (FLUMIZ).
Zinzani PL, Tani M, Pulsoni A, Gobbi M, Perotti A, De Luca S, Fabbri A, Zaccaria A, Voso MT, Fattori P, Guardigni L, Ronconi S, Cabras MG, Rigacci L, De Renzo A, Marchi E, Stefoni V, Fina M, Pellegrini C, Musuraca G, Derenzini E, Pileri S, Fanti S, Piccaluga PP, Baccarani M. Zinzani PL, et al. Among authors: fina m. Lancet Oncol. 2008 Apr;9(4):352-8. doi: 10.1016/S1470-2045(08)70039-1. Epub 2008 Mar 14. Lancet Oncol. 2008. PMID: 18342572 Clinical Trial.
Cyclophosphamide, doxorubicin, vincristine, methotrexate, bleomicin and prednisone plus rituximab in untreated young patients with low-risk (age-adjusted international prognostic index 0-1) diffuse large B-cell lymphoma.
Derenzini E, Stefoni V, Pellegrini C, Fina MP, Broccoli A, Venturini F, Gandolfi L, Pileri SA, Martelli M, Petti MC, Perrotti A, De Renzo A, Zaja F, Baccarani M, Zinzani PL. Derenzini E, et al. Among authors: fina mp. Leuk Lymphoma. 2009 Nov;50(11):1824-9. doi: 10.3109/10428190903216796. Leuk Lymphoma. 2009. PMID: 19814687 Clinical Trial.
A phase II trial of CHOP chemotherapy followed by yttrium 90 ibritumomab tiuxetan (Zevalin) for previously untreated elderly diffuse large B-cell lymphoma patients.
Zinzani PL, Tani M, Fanti S, Stefoni V, Musuraca G, Castellucci P, Marchi E, Farsad M, Fina M, Pellegrini C, Alinari L, Derenzini E, de Vivo A, Bacci F, Pileri S, Baccarani M. Zinzani PL, et al. Among authors: fina m. Ann Oncol. 2008 Apr;19(4):769-73. doi: 10.1093/annonc/mdm560. Epub 2008 Feb 25. Ann Oncol. 2008. PMID: 18303033 Free article. Clinical Trial.
A phase II trial of short course fludarabine, mitoxantrone, rituximab followed by ⁹⁰Y-ibritumomab tiuxetan in untreated intermediate/high-risk follicular lymphoma.
Zinzani PL, Tani M, Pulsoni A, De Renzo A, Stefoni V, Broccoli A, Montini GC, Fina M, Pellegrini C, Gandolfi L, Cavalieri E, Torelli F, Scopinaro F, Argnani L, Quirini F, Derenzini E, Rossi M, Pileri S, Fanti S, Baccarani M. Zinzani PL, et al. Among authors: fina m. Ann Oncol. 2012 Feb;23(2):415-20. doi: 10.1093/annonc/mdr145. Epub 2011 May 2. Ann Oncol. 2012. PMID: 21536660 Free article. Clinical Trial.
87 results